Biocon Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Biocon verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 3.3%, während die Gewinne der Branche Biotechs jährlich um gewachsen und zwar um 12%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 21.2%. Die Eigenkapitalrendite von Biocon beträgt 8% und die Nettomargen betragen 10%.

Wichtige Informationen

3.3%

Wachstumsrate der Gewinne

3.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie5.1%
Wachstumsrate der Einnahmen20.7%
Eigenkapitalrendite8.0%
Netto-Marge10.7%
Letzte Ertragsaktualisierung30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24
Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Recent updates

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Sep 20
These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29
Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Is Biocon (NSE:BIOCON) A Risky Investment?

Jun 11
Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Jun 11
Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24
Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

May 23
Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12
Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03
Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13
These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03
Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03
Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02
Is Biocon (NSE:BIOCON) Using Too Much Debt?

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26
Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28
Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26
Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17
Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05
Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13
Is Biocon (NSE:BIOCON) Using Too Much Debt?

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26
Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Mar 28
Is Biocon (NSE:BIOCON) Using Too Much Debt?

Aufschlüsselung der Einnahmen und Ausgaben

Wie Biocon Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NSEI:BIOCON Einnahmen, Ausgaben und Erträge (INR Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 24147,66015,80830,286-1,110
31 Mar 24147,55710,22528,525-838
31 Dec 23146,12512,00226,439-119
30 Sep 23135,9994,98424,819-1,238
30 Jun 23124,5734,19723,998-2,156
31 Mar 23111,7424,62723,331-3,922
31 Dec 2298,0913,88122,558-5,606
30 Sep 2290,4226,17021,920-5,825
30 Jun 2285,6297,08421,305-5,768
31 Mar 2281,8406,48420,539-4,764
31 Dec 2175,8006,72720,252-4,050
30 Sep 2172,6326,54219,935-3,581
30 Jun 2171,7266,85219,466-3,530
31 Mar 2171,4317,40517,485-3,507
31 Dec 2068,9135,99616,778-3,607
30 Sep 2067,5716,36215,906-3,596
30 Jun 2065,7966,87015,120-3,568
31 Mar 2063,0057,77116,545-3,458
31 Dec 1963,1508,38513,910-3,001
30 Sep 1961,0778,52913,093-2,746
30 Jun 1958,5659,91912,449-2,757
31 Mar 1955,1449,05311,653-2,699
31 Dec 1851,5518,22011,087-2,421
30 Sep 1846,7226,96710,496-2,449
30 Jun 1843,1984,1089,862-1,993
31 Mar 1841,2343,7249,311-1,747
31 Dec 1738,7923,6958,708-1,522
30 Sep 1738,5894,4898,297-1,257
30 Jun 1738,3615,2687,846-1,324
31 Mar 1738,9116,1217,510-1,283
31 Dec 1640,48711,6337,458-1,472
30 Sep 1638,11010,9617,038-1,468
30 Jun 1636,5399,3886,665-1,378
31 Mar 1633,4745,5046,128-1,320
31 Dec 1532,9977,3678,595-202
30 Sep 1532,3257,2478,366-196
30 Jun 1531,5285,2078,223-272
31 Mar 1530,8984,9745,371-1,321
31 Dec 1429,8074,0917,565-386
30 Sep 1429,1684,2317,360-561
30 Jun 1429,0144,2327,137-585
31 Mar 1428,7734,1387,035-642
31 Dec 1328,1805,4936,63647
30 Sep 1327,5105,3616,42847

Qualität der Erträge: BIOCON hat einen großen einmalig Gewinn von ₹13.5B, der sich auf die Finanzergebnisse der letzten 12 Monate auswirkt, an 30th June, 2024.

Wachsende Gewinnspanne: BIOCONDie aktuellen Gewinnspannen (6.9%) sind höher als im letzten Jahr (4.1%).


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: BIOCONIn den letzten 5 Jahren sind die Gewinne von 3.3% jährlich gestiegen.

Beschleunigtes Wachstum: BIOCONDas Gewinnwachstum des Unternehmens im letzten Jahr (276.7%) übertrifft seinen 5-Jahres-Durchschnitt (3.3% pro Jahr).

Erträge im Vergleich zur Industrie: BIOCON Das Gewinnwachstum im vergangenen Jahr (276.7%) übertraf das der Branche Biotechs 10.2% .


Eigenkapitalrendite

Hohe Eigenkapitalrendite: BIOCONDie Eigenkapitalrendite des Unternehmens (5.1%) wird als niedrig angesehen.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren